Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth

Core Insights - Harrow reaffirms its full-year 2025 revenue guidance of $270-280 million, highlighting strong execution across commercial and development programs [1] - The company is on track to double its VEVYE sales force, expand IHEEZO into office-based settings, and double the TRIESENCE sales force in surgical settings [1][2] - Harrow's ImprimisRx has settled regulatory matters with the California Board of Pharmacy and will exit the California market while focusing on other states [1][10] VEVYE Sales Force Expansion - Harrow plans to double the VEVYE sales force from approximately 50 to 100 territories by Memorial Day 2026, driven by recent coverage wins and expected stabilization of net pricing [3] IHEEZO Commercial Expansion - The company is expanding IHEEZO's focus to the office-based setting, targeting over 2.5 million annual procedures, which is expected to accelerate demand and adoption [4] TRIESENCE Sales Force Expansion - Harrow intends to double the surgical sales force for TRIESENCE, responding to positive clinical feedback and increasing demand metrics for the product [6] OneHarrow Initiative - The OneHarrow initiative aims to unify branding and operations under a single organization to enhance patient access, affordability, and clinical outcomes [7] Leadership Changes - Patrick W. Sullivan has been promoted to Chief Commercial Officer, focusing on strengthening Harrow's commercial foundation and aligning with the company's revenue goals [8] MELT-300 and MELT-210 Programs - Harrow is on track to submit New Drug Applications for MELT-300 and MELT-210, with all necessary studies initiated [1][9] ImprimisRx Regulatory Settlement - ImprimisRx has settled with the California Board of Pharmacy, agreeing to a fine of approximately $157,000, and will exit the California market effective February 1, 2026 [10]